Salute e Benessere

CROSSJECT presents its financial results and key highlights for the first half…

Press releaseCROSSJECT presents its financial results and key highlights for the first half of 2025Cash position: €6.3 million, compared to €7.0 million as of December 31 2024, demonstrating the Company's excellent control of its resources. Stable R&D investments and a €3.1 million increase in R&D reimbursements from BARDA1 for the first half of 2024, to €6.5 million, in line with the focus on regulatory development and batch manufacturing related to the registration...
Nasdaq GlobeNewswire
24/09/2025

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS…

Robert Montgomery, MD, PhD, New York University Langone Health, said: "There have been few major breakthroughs in desensitization strategies in kidney transplantation for the last 30 years. The unmet need remains high for kidney transplant patients who are considered highly sensitized, with many remaining on the wait list with little to no hope of receiving a suitable match for transplantation. The result from the US ConfIdeS trial are highly encouraging and demonstrate the significant…
PR Newswire
24/09/2025

Groupe Bastide completes the sale of Baywater Healthcare to Sapio Group

Caissargues, September 24, 2025 In line with the timetable set out in its 30 June 2025 communication announcing the agreement to sell Baywater Healthcare, a leading player in the UK respiratory care market, to Sapio Group, Groupe Bastide today announced that it has completed the sale of its UK subsidiary…
Actusnews Wire
24/09/2025

Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on…

H1 2025 results Activity and profitabilityH1 revenue: €387.8 million, down 5.4% at CER 1and on a like-for-like basis 2, mainly due to the decline in activity in FranceRestated EBITDA margin 3came out at 12.9%, compared with 15.4% a year earlier2025 financial targetsRevenue: slight decrease of approximately 1% at CER and on a like-for-like basisRestated EBITDA margin: between 12% and 13% of revenueFree cash flow: slightly negativeVillepinte, September 24, 2025,...
Nasdaq GlobeNewswire
24/09/2025

EUROBIO SCIENTIFIC: RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025

RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025 Revenue up 10% to €80.7 millionProprietary products account for 36% of revenue42% of revenue generated outside France2025 results impacted by the transfer of EndoPredict®/Prolaris® production to FranceFree cash flow after investment of €4.4 millionNet debt of €-2.2 million including EB Development current account Paris, September 24, 2025 - 5:40 p.m. - Eurobio Scientific ( FR0013240934, ALERS, eligible for...
Nasdaq GlobeNewswire
24/09/2025

Mobile Gamma Cameras Market Surges to USD 800 Million by 2033, Propelled by 7.3%…

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=840016 Download PDF Brochure:https://www.verifiedmarketreports.com/download-sample/?rid=840016 Browse in-depth TOC on Mobile Gamma Cameras Market 202 - Pages 126 – Tables 37 – Figures Scope of The Mobile Gamma Cameras Market Report Basda segment scope Global Mobile Gamma Cameras Market Overview Mobile Gamma Cameras Market: Trends and Opportunities ...
PR Newswire
24/09/2025

Mintel Most Innovative 2026: Recognizing the CPG Products Redefining the Future

"CPG innovation has never moved faster or felt more pressured. Consumers of all ages, especially Gen Alpha, Gen Z and Millennials, are eager to experiment and try new things, and they expect brands not just to keep up, but to stay a step ahead. Despite this urgency, true innovation is at an all-time low, with too many launches relying on safe, incremental updates," said Julie Lizer, President of Global Research and Insights at Mintel. "The tension between the pace of consumer…
PR Newswire
24/09/2025

In Vitro Diagnostics (IVD) Quality Control Market Poised for Strong Growth Amid…

The IVD Quality Control Market is witnessing significant growth as healthcare providers prioritize accurate and reliable diagnostic testing. The IVD Quality Control Market is witnessing significant growth as healthcare providers prioritize accurate and reliable diagnostic testing. For a detailed analysis of industry trends and growth drivers, explore the full In Vitro Diagnostics (IVD) Quality Control Market. Browse in-depth TOC 202 - Pages 126 - Tables 37 -...
PR Newswire
24/09/2025

Digital Migraine Treatment Devices Market to Reach USD 298.71 Million by 2030…

Download Exclusive Sample Report: https://www.datamintelligence.com/download-sample/digital-migraine-treatment-device-market Download Exclusive Sample Report:https://www.datamintelligence.com/download-sample/digital-migraine-treatment-device-market Browse in-depth TOC on "Digital Migraine Treatment Device Market" 70 – Tables 66 – Figures 195 – Pages Market Segmentation Analysis By Type By Application Hospitals remained the leading end-user in 2024, generating...
PR Newswire
24/09/2025

Financière de Tubize strengthens its expertise in the biopharma field by…

Since the appointment of Bruno Holthof as Chairman of the Board of Directors of the company in April 2025, the company's board has continued to strengthen its expertise in the biopharma field. This aims to best support UCB and contribute to the development of a sustainable biopharma ecosystem in Belgium, the United Kingdom, and other relevant geographical areas for UCB.The Extraordinary General Meeting held yesterday confirmed the appointment of two new directors, Iris Löw-Friedrich and...
Nasdaq GlobeNewswire
24/09/2025

Leo Cancer Care Raises $40 Million to Advance Upright Radiotherapy Innovations…

This substantial investment will accelerate commercialization of Leo Cancer Care's next-generation upright radiotherapy system, designed to enhance patient outcomes and broaden access to advanced cancer treatment. As part of the funding round, Catalio's Dr. Nicholas von Guionneau, joins Leo Cancer Care's board as an Observer. This substantial investment will accelerate commercialization of Leo Cancer Care's next-generation upright radiotherapy system, designed to enhance patient outcomes and...
PR Newswire
24/09/2025

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025, in Barcelona, Spain. The ECTRIMS Congress is the world’s largest annual...
Nasdaq GlobeNewswire
24/09/2025

EGI Launches Next-Generation HD-EEG Platform to Advance Understanding of Brain…

Innovator of HD-EEG releases world’s most advanced EEG brain monitoring technology for neuroscience research Electroencephalography (EEG) enables researchers and clinicians to noninvasively capture the brain’s electrical activity for insights into health, disease, and patient care. EGI innovated the gold standard in HD-EEG technology, cited in more than 4,000 research papers, including pivotal studies in depression, sleep, autism, Alzheimer’s disease and pharmaceutical development...
Nasdaq GlobeNewswire
24/09/2025

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in…

TOKYO and CAMBRIDGE, Mass., Sept.24, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI ® ” (brand name, generic name: lecanemab) for mild cognitive...
Nasdaq GlobeNewswire
24/09/2025

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an…

~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~~ Additional $100 million available subject to regulatory and financial milestones ~~ Additional $25 million available subject to Hercules’ approval ~~ Transaction provides financial flexibility and improves cost of capital ~ LEXINGTON, Mass. and AMSTERDAM, Sept.24, 2025(GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies...
Nasdaq GlobeNewswire
24/09/2025

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of…

~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~~ High-dose AMT-130 also demonstrated statistically significant slowing of disease progression as measured by TFC, a key secondary endpoint, and favorable trends across additional clinical measures ~~ Mean cerebrospinal fluid NfL levels were below baseline at 36 months ~~...
Nasdaq GlobeNewswire
24/09/2025

The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global…

In the Asia Pacific and Middle East region, two in three individuals (66%) skip routine heart tests, while nearly half (45%) do not recognize genetics as a risk factor of heart disease, according to the results of a recent survey commissioned by Novartis. Awareness of Lp(a) is even lower, with just 22% of respondent reporting they had heard of a test for the biomarker, while only 7% had taken it.7 In theAsia PacificandMiddle Eastregion, two in three individuals (66%) skip routine heart...
PR Newswire
24/09/2025

SM addresses rising consumer demand for beauty and wellness

"Beauty and wellness have shown significant growth across every demographic," said SM Retail President Jonathan Ng. "At SM, we will continue to be at the forefront of meeting customers' evolving preferences by offering enriching experiences through suitable and unique products and services." "Beauty and wellness have shown significant growth across every demographic," said SM Retail PresidentJonathan Ng. "At SM, we will continue to be at the forefront of…
PR Newswire
24/09/2025

Xeltis poised for commercialization following excellent clinical data from aXess…

The results from the trial showed that aXess delivered major improvements on all key clinical metrics compared to the standard of care. aXess demonstrated superior sustained patency across both primary and secondary outcomes*, compared to other arteriovenous grafts (AVG), while requiring fewer interventions, also showing a lower re-intervention rate and high infection resistance compared to fistulas. Many of the patients in the trial had a history of failed AVG's or fistulas for dialysis or had…
PR Newswire
24/09/2025

Leqembi® approved for the treatment of early Alzheimer's disease in Australia

Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two…
PR Newswire
24/09/2025

NHS Access to Medical Cannabis Could Unlock £13.3bn and Return Thousands to Work

Since its legalisation in 2018, private prescriptions have already contributed around £283 million in Gross Value Added (GVA) by helping people get well and back to work. Since its legalisation in 2018, private prescriptions have already contributed around £283 million in Gross Value Added (GVA) by helping people get well and back to work. Roughly 2.8 million people in the UK are currently locked out of employment due to long-term illness. Polling conducted alongside the Cebr study, found...
PR Newswire
24/09/2025

CARBIOS presents its 2025 half-year results and confirms its objective to build…

CARBIOS has reduced its operating expenses and has a strong cash position of€72 million as of June 30, 2025, providing a cash horizon of more than 12 monthsThe Longlaville plant construction project is now supported by:Major progress with public financers ADEME and the Regional CouncilClear interest from private investors, conditional upon the pre-sale of a significant portion of the future plant’s capacity, which has not yet been achievedRecent regulatory developments that...
Nasdaq GlobeNewswire
24/09/2025

New Novartis data further support benefits of Kesimpta® in relapsing MS…

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS)following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies 1 Following switch to Kesimpta, over 90% of people with RMS showed no evidence of disease activity (NEDA-3) and low annualized relapse rates (ARR) were observed 1 In the separate ALITHIOS open-label extension study,...
Nasdaq GlobeNewswire
24/09/2025

Roche presents new data for OCREVUS and fenebrutinib across broad patient…

OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMSOne-year data reinforce that majority of infants potentially exposed to OCREVUS during pregnancy or breastfeeding exhibit antibody responsesFenebrutinib two-year Phase II data demonstrate near-complete suppression of disease activity at 96 weeksBasel, 24 September 2025 - Roche (SIX: RO,...
Nasdaq GlobeNewswire
24/09/2025
Altri  Comunicati